|
|
Adjuplex+GLA |
|
Vaxjo ID |
118 |
|
Vaccine Adjuvant Name |
Adjuplex+GLA |
|
Adjuvant VO ID |
VO_0005302
|
|
Description |
synthetic derivative of natural compound / combination adjuvant with TLR4 receptor; induces Th1/Th17 immune response ; component of some current veterinary vaccines |
|
Stage of Development |
Research |
|
Location Licensed |
US (University of Wisconsin, Madison) |
|
Host Species for Testing |
Mouse |
|
Components |
polyacrylic-acid (carbomer) based adjuvant with soy lethicin --> acrylic-acid-based adjuvant (ADJ), in combination with Toll-like receptor (TLR) agonists glucopyranosyl lipid adjuvant (GLA) or CpG |
|
Storage |
Adjuplex is stored at 4C and GLA is stored at -20C |
|
Preparation |
nano emulsion of carbomer and soy lethicin |
|
Function |
Type: combination vaccine adjuvant. Target receptor: Toll-like receptor 4 (TLR4). Induces Th1/Th17 mixed immune profile. Adjuplex enhances cross presentation to CD8 T cells and GLA stimulates TLR4 signaling |
| References |
(Suresh, 2021): Vaccine Adjuvant Compendium (VAC) [https://vac.niaid.nih.gov/view?id=15]
Kingstad-Bakke et al., 2020: Kingstad-Bakke B, Toy R, Lee W, Pradhan P, Vogel G, Marinaik CB, Larsen A, Gates D, Luu T, Pandey B, Kawaoka Y, Roy K, Suresh M. Polymeric Pathogen-Like Particles-Based Combination Adjuvants Elicit Potent Mucosal T Cell Immunity to Influenza A Virus. Frontiers in immunology. 2020; 11; 559382. [PubMed: 33767689].
Marinaik et al., 2020: Marinaik CB, Kingstad-Bakke B, Lee W, Hatta M, Sonsalla M, Larsen A, Neldner B, Gasper DJ, Kedl RM, Kawaoka Y, Suresh M. Programming Multifaceted Pulmonary T Cell Immunity by Combination Adjuvants. Cell reports. Medicine. 2020; 1(6); 100095. [PubMed: 32984856].
|
|
